Prognostic and predictive biomarkers in renal cell carcinoma

被引：17

作者：

Vickers, Michael M. ^{[1
]}

Heng, Daniel Y. C. ^{[1
]}

机构：

[1] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB T2N 4N2, Canada

来源：

TARGETED ONCOLOGY | 2010年 / 5卷 / 02期

关键词：

Biomarkers; Renal cell carcinoma; von Hippel-Lindau (VHL); Vascular endothelial growth factor (VEGF); Hypoxia-inducible factor (HIF); Carbonic anhydrase IX (CAIX); CARBONIC-ANHYDRASE-IX; ENDOTHELIAL GROWTH-FACTOR; HIPPEL-LINDAU GENE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; INTEGRATED STAGING SYSTEM; KIDNEY CANCER; VHL GENE; TUMOR AGGRESSIVENESS; INDEPENDENT PREDICTOR; RADICAL NEPHRECTOMY;

D O I：

10.1007/s11523-010-0143-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the recent advances in targeted therapies, biomarkers in renal cell carcinoma (RCC) continue to be developed. Historically, information regarding prognosis has come from clinicopathologic variables, however in recent years much research has focused on the molecular basis of renal cell cancer. The discovery of reliable biomarkers in RCC could have an important impact on diagnosis, prognosis, and prediction of therapeutic benefit. To date, most biomarker research has centered on byproducts of the von Hippel-Lindau (VHL) pathway including VHL mutations, vascular endothelial growth factor (ligands and receptors), hypoxia-inducible factor, and carbonic anhydrase IX. This review examines these potential biomarkers, biomarker prognostic models, and molecular expression profiles in the field of renal cell carcinoma.

引用

页码：85 / 94

页数：10

共 78 条

[21] Expression of hypoxia-lnducible cell-surface transmembrane carbonic anhydrases in human cancer [J].

Ivanov, S ;

Liao, SY ;

Ivanova, A ;

Danilkovitch-Miagkova, A ;

Tarasova, N ;

Weirich, G ;

Merrill, MJ ;

Proescholdt, MA ;

Oldfield, EH ;

Lee, J ;

Zavada, J ;

Waheed, A ;

Sly, W ;

Lerman, MI ;

Stanbridge, EJ .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (03) :905-919

[22] Vascular endothelial growth factor as prognostic factor in renal cell carcinoma [J].

Jacobsen, J ;

Rasmuson, T ;

Grankvist, K ;

Ljungberg, S .

JOURNAL OF UROLOGY, 2000, 163 (01) :343-347

[23] Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease [J].

Janzen, NK ;

Kim, HL ;

Figlin, RA ;

Belldegrun, AS .

UROLOGIC CLINICS OF NORTH AMERICA, 2003, 30 (04) :843-+

[24]

Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]

[25] Gene signatures of progression and metastasis in renal cell cancer [J].

Jones, J ;

Otu, H ;

Spentzos, D ;

Kolia, S ;

Inan, M ;

Beecken, WD ;

Fellbaum, C ;

Gu, XS ;

Joseph, M ;

Pantuck, AJ ;

Jonas, D ;

Libermann, TA .

CLINICAL CANCER RESEARCH, 2005, 11 (16) :5730-5739

[26] Identification of a MicroRNA Panel for Clear-cell Kidney Cancer [J].

Juan, David ;

Alexe, Gabriela ;

Antes, Travis ;

Liu, Huiqing ;

Madabhushi, Anant ;

Delisi, Charles ;

Ganesan, Shridhar ;

Bhanot, Gyan ;

Liou, Louis S. .

UROLOGY, 2010, 75 (04) :835-841

[27] The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma [J].

Kaelin, William G., Jr. .

CLINICAL CANCER RESEARCH, 2007, 13 (02) :680S-684S

[28] A postoperative prognostic nomogram for renal cell carcinoma [J].

Kattan, MW ;

Reuter, V ;

Motzer, RJ ;

Katz, J ;

Russo, P .

JOURNAL OF UROLOGY, 2001, 166 (01) :63-67

[29] A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes [J].

Kent, O. A. ;

Mendell, J. T. .

ONCOGENE, 2006, 25 (46) :6188-6196

[30] Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma [J].

Kim, HL ;

Seligson, D ;

Liu, XL ;

Janzen, N ;

Bui, MHT ;

Yu, H ;

Shi, T ;

Belldegrun, AS ;

Horvath, S ;

Figlin, RA .

JOURNAL OF UROLOGY, 2005, 173 (05) :1496-1501

← 1 2 3 4 5 6 7 8 →